Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 903× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KOLD | VRTX | |
|---|---|---|
Market Cap | $141.25M | $127.55B |
Volume | 5,492,367 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $557.96 |
52-Week Low | $13.58 | $407.37 |
Typical Hold Time | 10 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $25.68, up 3.38% today, but faces bearish technical signals with 15 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal strong bearish pressure. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy commodities. Support levels at $23-25 provide near-term downside protection.
The bearish technical setup and natural gas market headwinds suggest cautious near-term outlook. Investment opportunity exists if the stock holds above key support levels amid energy market volatility. Primary risks include sustained natural gas price pressure and production oversupply concerns that could impact energy sector performance.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
